Clinical Trial Update: SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial of Semaxanib (SU5416) for metastatic renal cell carcinoma that failed prior therapy was terminated. This document serves as a status update on the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Semaxanib (SU5416)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Status: TERMINATED